Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(02): 185-188
DOI: 10.1055/s-0042-1743505
Trainees' Corner

Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy

Arpit Jain
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Venkata Pradeep Babu Koyyala
2   Department of Medical Oncology, ACCF Cancer Hospital, Bihaguri, Tezpur, India
,
Satya Narayan
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Satyajeet Soni
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Pallavi Redhu
1   Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Akanksha Jaju
3   Department of Pathology, Sardar Vallabh Bhai Patel Hospital, New Delhi, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Immune checkpoint inhibitor (ICI) restores an efficient antitumor T cell response against tumor cells fostering durable responses that can persist even after the treatment. However, these treatment effects can manifest as an unusual pattern of disease progression, pseudo-progression, or hyper-progression. Differentiating hyper progressive disease (HPD) from pseudo-progression has significant clinical implications and further decision-making for the patient on ICI. HPD is a dramatic acceleration of the rate of tumor progression with the advent of immunotherapeutic agents causing detrimental effects on the disease outcome.

Keywords

hyper-progression - immunotherapy - medical oncology - PD1/PDL1

Authors' Contributions

The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and each author believes that the manuscript represents honest work.




Publication History

Article published online:
18 April 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Champiat S, Dercle L, Ammari S. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017; 23 (08) 1920-1928
    CrossrefPubMedGoogle Scholar
  • 2 Ferrara R, Mezquita L, Texier M. et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018; 4 (11) 1543-1552 DOI: 10.1001/jamaoncol.2018.3676.
    CrossrefPubMedGoogle Scholar
  • 3 Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017; 23 (15) 4242-4250
    CrossrefPubMedGoogle Scholar
  • 4 Singavi AK, Menon S, Kilari D. et al. Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)–analysis of somatic alterations (SAs). Ann Oncol 2017; 28: v405
    CrossrefGoogle Scholar
  • 5 Weiss GJ, Beck J, Braun DP. et al. Tumor cell–free DNA copy number instability predicts therapeutic response to immunotherapy. Clin Cancer Res 2017; 23 (17) 5074-5081
    CrossrefPubMedGoogle Scholar
  • 6 Saâda-Bouzid E, Defaucheux C, Karabajakian A. et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017; 28 (07) 1605-1611
    CrossrefPubMedGoogle Scholar
  • 7 Kim CG, Kim KH, Pyo KH. et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol 2019; 30 (07) 1104-1113
    CrossrefPubMedGoogle Scholar